The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, according to a ...

People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...